インスリン抵抗性および高インスリン血症:ヒトの左心室質量と独立した関係はありません
A Q Galvan1, F Galetta, A Natali
1Department of Internal Medicine, University of Pisa School of Medicine, and the Metabolism Unit of the CNR Institute of Clinical Physiology, University of Pisa, Italy.
Circulation
|November 1, 2000
まとめ
インスリン濃度とインスリン感受性は,糖尿病でない個人の左心室質量を独立して予測することはできません. 体重と血圧は,心臓の構造に影響を与える重要な要因です.
科学分野:
- 心血管の生理学 心血管の生理学
- メタボリック・ヘルス (代謝健康)
背景:
- ハイパーインスリン血症とインスリン抵抗性は,心筋縮に寄与すると疑われています.
- これらの代謝因子と心臓の変化を結びつける既存のヒトの証拠は,まだ定かではありません.
研究 の 目的:
- インスリンダイナミクス (濃度,分泌,感受性) と,糖尿病のない成人における左心室質量 (LVM) の間の独立した関係を調査する.
- 肥満や高血圧などの要因を考慮して,LVMの独立した予測要因を特定する.
主な方法:
- 異なる年齢,BMI,血圧の50人の非糖尿病患者を研究した.
- 血インスリン,インスリン感受性 (インスリンクランプを用いて) と左心室質量 (心拍) を測定した.
- 混同変数を調整するために多変数回帰分析を使用しました.
主要な成果:
- 肥満および高血圧の被験者は,正常血圧の非肥満の個人に比べて,左心室の質量が著しく高かった.
- インスリン濃度,分泌,または感受性は,BMIと血圧を調整した後,LVMと独立して相関しませんでした.
- 収縮性血圧とBMIは,LVMの唯一の独立した予測指標であり,高血圧は肥満よりも大きな影響を及ぼします.
結論:
- 非糖尿病患者では,インスリン動態は左心室質量の独立した決定因子ではありません.
- 体重と高血圧は,左心室質量増加に関連する主要な独立した要因です.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...